Historical Valuation
Candel Therapeutics Inc (CADL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.04. The fair price of Candel Therapeutics Inc (CADL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：5.71
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Candel Therapeutics Inc (CADL) has a current Price-to-Book (P/B) ratio of 3.73. Compared to its 3-year average P/B ratio of 0.83 , the current P/B ratio is approximately 347.48% higher. Relative to its 5-year average P/B ratio of 1.11, the current P/B ratio is about 235.31% higher. Candel Therapeutics Inc (CADL) has a Forward Free Cash Flow (FCF) yield of approximately -11.30%. Compared to its 3-year average FCF yield of -45.63%, the current FCF yield is approximately -75.24% lower. Relative to its 5-year average FCF yield of -38.87% , the current FCF yield is about -70.93% lower.
P/B
Median3y
0.83
Median5y
1.11
FCF Yield
Median3y
-45.63
Median5y
-38.87
Competitors Valuation Multiple
AI Analysis for CADL
The average P/S ratio for CADL competitors is 4863.59, providing a benchmark for relative valuation. Candel Therapeutics Inc Corp (CADL.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CADL
1Y
3Y
5Y
Market capitalization of CADL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CADL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CADL currently overvalued or undervalued?
Candel Therapeutics Inc (CADL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.04. The fair price of Candel Therapeutics Inc (CADL) is between NaN to NaN according to relative valuation methord.
What is Candel Therapeutics Inc (CADL) fair value?
CADL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Candel Therapeutics Inc (CADL) is between NaN to NaN according to relative valuation methord.
How does CADL's valuation metrics compare to the industry average?
The average P/S ratio for CADL's competitors is 4863.59, providing a benchmark for relative valuation. Candel Therapeutics Inc Corp (CADL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Candel Therapeutics Inc (CADL) as of Jan 11 2026?
As of Jan 11 2026, Candel Therapeutics Inc (CADL) has a P/B ratio of 3.73. This indicates that the market values CADL at 3.73 times its book value.
What is the current FCF Yield for Candel Therapeutics Inc (CADL) as of Jan 11 2026?
As of Jan 11 2026, Candel Therapeutics Inc (CADL) has a FCF Yield of -11.30%. This means that for every dollar of Candel Therapeutics Inc’s market capitalization, the company generates -11.30 cents in free cash flow.
What is the current Forward P/E ratio for Candel Therapeutics Inc (CADL) as of Jan 11 2026?
As of Jan 11 2026, Candel Therapeutics Inc (CADL) has a Forward P/E ratio of -6.10. This means the market is willing to pay $-6.10 for every dollar of Candel Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Candel Therapeutics Inc (CADL) as of Jan 11 2026?
As of Jan 11 2026, Candel Therapeutics Inc (CADL) has a Forward P/S ratio of 0.00. This means the market is valuing CADL at $0.00 for every dollar of expected revenue over the next 12 months.